VOLUNTARY ANNOUNCEMENT - LATEST RESEARCH DATA ON TQF6422 “ACTRII A/B MONOCLONAL ANTIBODY” PRESENTED AT ECO 2026

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE STRATEGIC COLLABORATION WITH GSK

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR M701 “CD3/EpCAM BISPECIFIC ANTIBODY”

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLMENT IN THE PHASE III REGISTRATIONAL CLINICAL TRIAL OF CAFELKIBART “CCR8 MONOCLONAL ANTIBODY” FOR SECOND-LINE GASTRIC CANCER